Healthcare Services

Pelvic Inflammatory Disease (PID) Treatment Market Outlook 2026–2030 with Major Growth Drivers and Emerging Industry Trends

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Pelvic Inflammatory Disease (PID) Treatment Market By The End Of 2030?

The pelvic inflammatory disease (pid) treatment market has experienced robust expansion in recent years. Its valuation is set to grow from $4.74 billion in 2025 to $5 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The historical growth of this market is attributable to a high prevalence of sexually transmitted infections, limited public awareness of PID, a common reliance on broad-spectrum antibiotics, delayed diagnoses stemming from asymptomatic cases, and inadequate access to specialized gynecological care.

The pelvic inflammatory disease (pid) treatment market size is projected to experience substantial expansion over the coming years. This market is set to reach $6.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period stems from factors such as the increasing embrace of combination antibiotic therapy, a rise in the application of hormonal therapy for prevention, significant progress in minimally invasive surgical techniques, the expansion of telehealth and remote monitoring services, and enhanced awareness and educational initiatives aimed at early detection. Key developments expected during this period involve the greater application of AI for prompt diagnosis and risk assessment, a rising uptake of genomics-driven personalized treatment strategies, the incorporation of cloud computing and big data for patient oversight and administration, the deployment of IoT-enabled devices for distant symptom monitoring, and the introduction of smart manufacturing processes in the production of antibiotics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21251&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Pelvic Inflammatory Disease (PID) Treatment Market?

The growing incidence of sexually transmitted infections is anticipated to stimulate expansion in the pelvic inflammatory disease (PID) treatment market in the coming years. STIs, which are infections primarily transmitted through sexual contact including vaginal, anal, or oral sex, are caused by bacteria, viruses, or parasites. The heightened occurrence of STIs can be attributed to factors like engaging in risky sexual practices, unprotected intercourse, inadequate awareness, and delays in testing and treatment. Pelvic inflammatory disease (PID) treatment plays a crucial role in addressing STIs by employing antibiotics to eradicate the bacteria causing infection, preventing complications like chronic pelvic pain and infertility, and mitigating the likelihood of recurrent infections. For instance, a report from the UK Health Security Agency (UKHSA), a UK-based government entity, published in October 2024, indicated that England registered 6,008 new human immunodeficiency virus (HIV) diagnoses in 2023, representing a 51% increase from the 3,975 diagnoses recorded in 2022. Consequently, the rising prevalence of sexually transmitted infections is a key driver for the growth of the pelvic inflammatory disease (PID) treatment market.

Which Segment Classifications Shape The Pelvic Inflammatory Disease (PID) Treatment Market?

The pelvic inflammatory disease (pid) treatment market covered in this report is segmented –

1) By Treatment Type: Antibiotic Therapy, Surgery, Pain Management

2) By Route Of Administration: Oral, Intravenous, Intramuscular

3) By End User: Hospitals, Clinics, Homecare

Subsegments:

1) By Antibiotic Therapy: Broad-spectrum Antibiotics, Combination Antibiotic Therapy, Oral Antibiotics, Intravenous Antibiotics

2) By Surgery: Laparoscopy, Hysterectomy, Tubal Surgery

3) By Pain Management: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen, Localized Pain Management

What Trends Are Advancing Progress In The Pelvic Inflammatory Disease (PID) Treatment Market?

Major companies operating in the pelvic inflammatory disease (PID) treatment market are increasingly focusing on innovative formulations, such as probiotic supplements, to enhance the effectiveness of treatments, restore the balance of vaginal microbiota, and reduce the recurrence of infections in patients with PID. A probiotic supplement is defined as a product containing beneficial live bacteria or yeasts that help maintain or restore a healthy balance of gut and vaginal microbiota. For instance, in November 2024, Lee Health Domain, an India-based pharmaceutical company, introduced V-Ferin, a probiotic supplement developed to support vaginal health. Formulated with Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract, V-Ferin aims to restore the natural microbiome and prevent common vaginal infections like bacterial vaginosis and yeast infections. Given that approximately 25-30% of women are affected by these conditions, which can progress to pelvic inflammatory disease if left untreated, V-Ferin offers a novel solution to improve health and prevent complications.

Which Companies Are Expanding Their Footprint In The Pelvic Inflammatory Disease (PID) Treatment Market?

Major companies operating in the pelvic inflammatory disease (pid) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., Amagen India Life Sciences

Read the full pelvic inflammatory disease (pid) treatment market report here:

https://www.thebusinessresearchcompany.com/report/pelvic-inflammatory-disease-pid-treatment-global-market-report

Which Regions Are Projected To Dominate The Pelvic Inflammatory Disease (PID) Treatment Market In The Coming Years?

North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pelvic inflammatory disease (pid) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pelvic Inflammatory Disease (PID) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21251&type=smp

Browse Through More Reports Similar to the Global Pelvic Inflammatory Disease (PID) Treatment Market 2026, By The Business Research Company

Urinary Tract Cancer Global Market Report

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Interstitial Cystitis Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/interstitial-cystitis-drugs-global-market-report

Ovarian Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795